Is CRISPR Therapeutics Stock a Buy? One Analyst Thinks the Biotech Is “Very Undervalued.” The Motley Fool 2 days
‘Don’t be Afraid’: How His Father’s Battle With Dementia Inspired This Entrepreneur’s Mission Entrepreneur 2 days
Buffett Back at the Buy Window, Plus Insider Buying at a Refiner, Biotechs, and More 24/7 Wall St. 5 days
Sarepta Therapeutics’ stock soars 38% after FDA expands use of its Duchenne muscular-dystrophy drug MarketWatch 1 week
Intra-Cellular Therapies Eyes $1.7 Billion Opportunity After Phase 3 Win Investor's Business Daily 1 week
Zal Bilimoria just raised a $50M fourth Refactor Capital fund, and still relishes his solo GP status TechCrunch 1 week
Nurix Therapeutics, With 345% Run, Posts A ‘Clear Win’ In Leukemia Treatment Investor's Business Daily 2 weeks
Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word. The Motley Fool 2 weeks
The ‘Impressive’ Results That Sent Top 1% Avidity Biosciences To A Record Investor's Business Daily 2 weeks